ERBB2 and cancer: In an in silico evaluation, [134] classified drugs involved in cancer therapy [175] could be separated into two general classes, i.e., (i) agents that target specific receptors such as those including angiogenesis, cell cycle, microtubule/cytoskeleton, EGFR/FGFR/HER2/IGFR signaling pathways, Ras-Raf-MEK-MAPK-ERK pathway, mTOR pathway, PI3K-AKT pathway, HDAC epigenetic agents, and HSP90s; and (ii) broad cytotoxic chemotherapeutics including nucleotide synthesis, metabolism, DNA cross-linker and multiple targets, defined as various.